Skip to main content
SpringerLink
Log in

Management of Bone Metastases

  • Chapter
  • First Online:
Prostate Cancer: A Comprehensive Perspective

  • 2936 Accesses

Abstract

Bone metastases are a common manifestation of secondary spread of prostate cancer [1]. The incidence increases with stage of the disease and factors that contribute to increased risk categories such as T-stage, level of PSA, and high Gleason score.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171(6 Pt 1):2122–7.

    Article  PubMed  Google Scholar 

  2. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer. 2000;88(12 Suppl):2952–60.

    Article  PubMed  CAS  Google Scholar 

  3. Orr FW, et al. Pathophysiologic interactions in skeletal metastasis. Cancer. 2000;88(12 Suppl):2912–8.

    Article  PubMed  CAS  Google Scholar 

  4. Jimenez-Andrade JM, et al. Bone cancer pain. Ann N Y Acad Sci. 2010;1198:173–81.

    Article  PubMed  Google Scholar 

  5. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032–45.

    Article  PubMed  CAS  Google Scholar 

  6. Body JJ, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006;12(4):1221–8.

    Article  PubMed  CAS  Google Scholar 

  7. Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care. 2009;3(1):1–6.

    Article  PubMed  Google Scholar 

  8. Morris MJ, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002;59(6):913–8.

    Article  PubMed  Google Scholar 

  9. Beheshti M, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2009;11(6):446–54.

    Article  PubMed  Google Scholar 

  10. Jeschke S, Schweigreiter E, Janetschek G. Role of imaging in prostate cancer: a review of imaging decisions. MRI. 2009;13:68–87.

    Google Scholar 

  11. Bouchelouche K, Capala J, Oehr P. Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer. Curr Opin Oncol. 2009;21(5):469–74.

    Article  PubMed  Google Scholar 

  12. Helyar V, et al. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging. 2010;37(4):706–13.

    Article  PubMed  Google Scholar 

  13. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 2000;88(12 Suppl):2989–94.

    Article  PubMed  CAS  Google Scholar 

  14. Dy SM, et al. Evidence-based standards for cancer pain management. J Clin Oncol. 2008;26(23):3879–85.

    Article  PubMed  Google Scholar 

  15. Reid C, Davies A. The World Health Organization three-step analgesic ladder comes of age. Palliat Med. 2004;18(3):175–6.

    Article  PubMed  Google Scholar 

  16. Smith MR, Brown GA, Saad F. New opportunities in the management of prostate cancer–related bone complications. Urol Oncol Semin Original Investig. 2009;27(6):S1.

    Article  Google Scholar 

  17. Cumming D, et al. Metastatic bone disease: the requirement for improvement in a multidisciplinary approach. Int Orthop. 2009;33(2):493–6.

    Article  PubMed  CAS  Google Scholar 

  18. Healey JH, Brown HK. Complications of bone metastases: surgical management. Cancer. 2000;88(12 Suppl):2940–51.

    Article  PubMed  CAS  Google Scholar 

  19. Tokuhashi Y, et al. Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976). 1990;15(11):1110–3.

    Article  CAS  Google Scholar 

  20. Patchell RA, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643–8.

    Article  PubMed  Google Scholar 

  21. Chi JH, et al. Selecting treatment for patients with malignant epidural spinal cord compression-does age matter?: results from a randomized clinical trial. Spine (Phila Pa 1976). 2009;34(5):431–5.

    Article  Google Scholar 

  22. Thomas KC, et al. Cost-effectiveness of surgery plus radiotherapy versus radiotherapy alone for metastatic epidural spinal cord compression. Int J Radiat Oncol Biol Phys. 2006;66(4):1212–8.

    Article  PubMed  Google Scholar 

  23. Burton AW, Rhines LD, Mendel E. Vertebroplasty and kyphoplasty: a comprehensive review. Neurosurg Focus. 2005;18(3):e1.

    Article  PubMed  Google Scholar 

  24. Maranzano E, et al. Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. J Clin Oncol. 2005;23(15):3358–65.

    Article  PubMed  Google Scholar 

  25. Wu JS, et al. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003;55(3):594–605.

    Article  PubMed  Google Scholar 

  26. van der Linden YM, et al. Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys. 2004;59(2):528–37.

    Article  PubMed  Google Scholar 

  27. Steenland E, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol. 1999;52(2):101–9.

    Article  PubMed  CAS  Google Scholar 

  28. Sze WM, et al. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy–a systematic review of randomised trials. Clin Oncol (R Coll Radiol). 2003;15(6):345–52.

    Article  CAS  Google Scholar 

  29. Roos DE, et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol. 2005;75(1):54–63.

    Article  PubMed  Google Scholar 

  30. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group. Cancer. 1982;50(5):893–9.

    Article  PubMed  CAS  Google Scholar 

  31. Salazar OM, et al. Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the International Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol Phys. 2001;50(3):765–75.

    Article  PubMed  CAS  Google Scholar 

  32. Itshayek E, et al. Timing of surgery and radiotherapy in the management of metastatic spine disease: a systematic review. Int J Oncol. 2010;36(3):533–44.

    PubMed  Google Scholar 

  33. Townsend PW, et al. Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopedic stabilization of impending or pathologic fractures due to metastatic disease. J Clin Oncol. 1994;12(11):2345–50.

    PubMed  CAS  Google Scholar 

  34. Young RF, Post EM, King GA. Treatment of spinal epidural metastases. Randomized prospective comparison of laminectomy and radiotherapy. J Neurosurg. 1980;53(6):741–8.

    Article  PubMed  CAS  Google Scholar 

  35. Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys. 1995;32(4):959–67.

    Article  PubMed  CAS  Google Scholar 

  36. Gerszten PC, Mendel E, Yamada Y. Radiotherapy and radiosurgery for metastatic spine disease. Spine. 2009;34:S78–92.

    Article  PubMed  Google Scholar 

  37. Sahgal A, et al. Stereotactic body radiotherapy is effective salvage therapy for patients with prior radiation of spinal metastases. Int J Radiat Oncol Biol Phys. 2009;74(3):723–31.

    Article  PubMed  Google Scholar 

  38. Sahgal A, Larson DA, Chang EL. Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys. 2008;71(3):652–65.

    Article  PubMed  Google Scholar 

  39. Papatheofanis FJ, Williams E, Chang SD. Cost-utility analysis of the CyberKnife system for metastatic spinal tumors. Neurosurgery. 2009;64(2 Suppl):A73–83.

    Article  PubMed  Google Scholar 

  40. Greco C, Zelefsky MJ, Lovelock M, et al. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int J Radiat Oncol Biol Phys. 2011;79:1151–7.

    Article  PubMed  Google Scholar 

  41. RTOG 0621. Image-guided radiosurgery or stereotactic body radiation therapy in treating patients with localized spine metastases. http://clinicaltrials.gov/ct2/show/NCT00922974?term=RTOG+0631&rank=1.

  42. Breen SL, Powe JE, Porter AT. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med. 1992;33(7):1316–23.

    PubMed  CAS  Google Scholar 

  43. Lewington VJ, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991;27(8):954–8.

    Article  PubMed  CAS  Google Scholar 

  44. Porter AT, McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin Oncol. 1993;20(3 Suppl 2):38–43.

    PubMed  CAS  Google Scholar 

  45. Sartor O, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940–5.

    Article  PubMed  Google Scholar 

  46. Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med. 2010;40(2):89–104.

    Article  PubMed  Google Scholar 

  47. NCT00699751 A phase III study of alpharadin (radium-223) in patients with symptomatic hormone refractory prostate cancer with skeletal metastases. http://www.clinicaltrials.gov/ct2/show/NCT00699751?term=alsympca&rank=1.

  48. Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587–94.

    Article  PubMed  CAS  Google Scholar 

  49. Ross JR, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess. 2004;8(4):1–176.

    PubMed  CAS  Google Scholar 

  50. Saad F, et al. Long-term efficacy of zoledronic acid for the pre-vention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879–82.

    Article  PubMed  CAS  Google Scholar 

  51. Saad F, et al. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer. 2007;5(6):390–6.

    Article  PubMed  CAS  Google Scholar 

  52. Ernst DS, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003;21(17):3335–42.

    Article  PubMed  CAS  Google Scholar 

  53. Small EJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21(23):4277–84.

    Article  PubMed  CAS  Google Scholar 

  54. Dearnaley DP, et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009;10(9):872–6.

    Article  PubMed  CAS  Google Scholar 

  55. Saunders Y, et al. Systematic review of bisphosphonates for hypercalcaemia of malignancy. Palliat Med. 2004;18(5):418–31.

    Article  PubMed  CAS  Google Scholar 

  56. Sorensen S, et al. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer. 1994;30A(1):22–7.

    Article  PubMed  CAS  Google Scholar 

  57. Tannock IF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

    Article  PubMed  CAS  Google Scholar 

  58. Petrylak DP, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.

    Article  PubMed  CAS  Google Scholar 

  59. Fizazi K, et al. Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int. 2010;105(6):748–67.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Uro-Oncology Service, Peter McCallum Cancer Centre, St. Andrew’s Place, East Melbourne, VIC, 3002, Australia

    Keen-Hun Tai MBBS, FRANZCR & Farshad Foroudi MBBS, MPA, FRANZCR

Authors
  1. Keen-Hun Tai MBBS, FRANZCR
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farshad Foroudi MBBS, MPA, FRANZCR
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keen-Hun Tai MBBS, FRANZCR .

Editor information

Editors and Affiliations

  1. New York Presbyterian Hospital, Brady Urologic Health Center, Weill Cornell Medical Center, East 68th Street 525, New York, 10021, New York, USA

    Ashutosh Tewari

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Tai, KH., Foroudi, F. (2013). Management of Bone Metastases. In: Tewari, A. (eds) Prostate Cancer: A Comprehensive Perspective. Springer, London. https://doi.org/10.1007/978-1-4471-2864-9_87

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2864-9_87

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2863-2

  • Online ISBN: 978-1-4471-2864-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation